Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in E-TCL1 mice

Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated pathways in CLL cells, that are known drivers of disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Bola S., Yazdanparast, Haniyeh, Demerdash, Yasmin, Roessner, Philipp M., Schulz, Ralph, Lichter, Peter, Stilgenbauer, Stephan, Seiffert, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017821/
https://www.ncbi.nlm.nih.gov/pubmed/32139435
http://dx.doi.org/10.3324/haematol.2019.238154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017821/
https://www.ncbi.nlm.nih.gov/pubmed/32139435
http://dx.doi.org/10.3324/haematol.2019.238154

Ejemplares similares